Apellis Pharmaceuticals Unusual Options Activity For September 22

A whale with a lot of money to spend has taken a noticeably bearish stance on Apellis Pharmaceuticals.

Looking at options history for Apellis Pharmaceuticals APLS we detected 11 strange trades.

If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 63% with bearish.

From the overall spotted trades, 6 are puts, for a total amount of $287,660 and 5, calls, for a total amount of $364,100.

Get Started

Earn 7.2% — No Matter What the Fed Does

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Get Started

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $50.0 for Apellis Pharmaceuticals over the last 3 months.

Volume & Open Interest Development

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Apellis Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apellis Pharmaceuticals's whale trades within a strike price range from $30.0 to $50.0 in the last 30 days.

Apellis Pharmaceuticals Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Where Is Apellis Pharmaceuticals Standing Right Now?

• With a volume of 2,307,115, the price of APLS is down -6.57% at $43.91.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 45 days.

What The Experts Say On Apellis Pharmaceuticals:

• Needham downgraded its action to Buy with a price target of $60
• HC Wainwright & Co. downgraded its action to Buy with a price target of $82
• Wells Fargo upgraded its action to Overweight with a price target of $64
• HC Wainwright & Co. downgraded its action to Buy with a price target of $82
• Stifel has decided to maintain their Buy rating on Apellis Pharmaceuticals, which currently sits at a price target of $65.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Apellis Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.